Capital Fund Management S.A. Sells 70,348 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Capital Fund Management S.A. sold 70.6% of its stake in Lantheus Holdings, Inc., resulting in ownership of 29,225 shares valued at $2.85 million at the end of the first quarter.
• Several analysts have recently upgraded their ratings on Lantheus, with five giving it a "Buy" rating and a consensus target price of $105.50.
• Lantheus reported a lower-than-expected EPS of $1.57 for the last quarter, missing estimates by $0.08, and experienced a year-over-year revenue decline of 4.1%.

Capital Fund Management S.A. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 70.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,225 shares of the medical equipment provider's stock after selling 70,348 shares during the period. Capital Fund Management S.A.'s holdings in Lantheus were worth $2,852,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Signaturefd LLC increased its holdings in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after buying an additional 116 shares in the last quarter. Hughes Financial Services LLC bought a new stake in Lantheus during the first quarter valued at $81,000. UMB Bank n.a. boosted its position in shares of Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after purchasing an additional 381 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after purchasing an additional 633 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after purchasing an additional 298 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. JMP Securities cut their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. William Blair reissued a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Mizuho dropped their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Finally, Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $105.50.

Lantheus Trading Down 1.3%

Shares of NASDAQ LNTH traded down $0.70 during midday trading on Friday, hitting $54.80. 605,571 shares of the company traded hands, compared to its average volume of 1,202,653. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The stock has a 50-day moving average price of $69.69 and a 200 day moving average price of $83.36. The firm has a market cap of $3.73 billion, a P/E ratio of 14.58 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same quarter in the prior year, the firm earned $1.80 EPS. Lantheus's quarterly revenue was down 4.1% compared to the same quarter last year. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,838,066 shares of company stock worth $384,430,031 over the last 90 days. 1.50% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.